CytoDyn Registers 795M Shares for Resale — Massive Overhang on a Going-Concern Biotech

summarizeSummary

CytoDyn registered 794.97 million shares for resale by selling stockholders, including 384.9 million shares underlying warrants. The company gets no proceeds from the resale itself, but could receive up to $94.6 million if all warrants are exercised for cash.

check_boxKey Events · Financing and Capital Events · CYDY

• 795M Shares Registered for Resale

  S-3 registers 410,046,456 common shares and 384,925,833 warrant shares for resale by selling stockholders — approximately 54% of the 1,469,518,019 shares outstanding as of September 24, 2026.

• No Proceeds to Company from Resale

  CytoDyn will not receive any proceeds from sales by selling stockholders. Only if all warrants are exercised for cash would the company receive up to approximately $94.6 million.

• Warrant Exercise Prices Range $0.09–$0.50

  Warrants covered by the registration have exercise prices from $0.09387 to $0.50 per share, with the weighted average exercise price of outstanding warrants at $0.28.

• Going-Concern Backdrop

  The registration follows the August 31, 2026 10-K that disclosed a going-concern warning and a $42.7 million net loss, amplifying the dilution risk from this large resale shelf.

auto_awesomeAnalysis · CYDY · Life Sciences

CytoDyn has filed an S-3 to register nearly 795 million shares for resale by selling stockholders — roughly 54% of its current 1.47 billion shares outstanding. The company receives no proceeds from these sales; only if all 384.9 million warrants are exercised for cash would it collect up to $94.6 million. This comes just weeks after the 10-K disclosed a going-concern warning and a $42.7 million net loss, meaning the registration converts a large block of previously restricted shares into freely tradable stock at a time when the company is already under severe financial pressure. The sheer size of the overhang — over half the current share count — is the dominant risk for existing holders.